Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31399585 | 1.00 | DUT (0.33) | DUTALOX15 | |
| SCHEMBL15975343 | 0.98 | DUT (0.34) | DUTALOX15 | |
| SCHEMBL4345547 | 0.83 | BTN3A1 (0.33) | DUT | |
| SCHEMBL4345540 | 0.83 | BTN3A1 (0.33) | DUT | |
| SCHEMBL1691511 | 0.81 | BTN3A1 (0.35) | DUT | |
| SCHEMBL1691509 | 0.81 | BTN3A1 (0.35) | DUT | |
| SCHEMBL14245094 | 0.80 | DUT (0.42) | DUT | |
| SCHEMBL18384339 | 0.80 | TBXAS1 (0.34) | DUT | |
| SCHEMBL9007756 | 0.80 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.80 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | DUT 1358/4885ALOX15 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.